Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Item No. 38166

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Klotho-derived peptide 1 (KP1) is an antifibrotic peptide antagonist of TGF-β receptor type 2 (TGFBR2) that corresponds to amino acids 56-87 of human Klotho, an anti-aging protein involved in TGF-β, Wnt, and FGF2 signaling.1 It binds to TGFBR2 (Kd = 1.41 µM) and inhibits TGF-β-induced increases in fibronectin and α-smooth muscle actin (α-SMA) levels in NRK-49F rat fibroblasts. In vivo, KP1 (1 mg/kg per day) selectively localizes to damaged kidneys and reduces fibrosis and serum creatinine and blood urea nitrogen (BUN) levels in mouse models of renal fibrosis. It also prevents severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein-induced aggravation of acute kidney injury, reduces bile duct ligation-induced cholestatic fibrosis, and decreases acute liver injury-induced hepatic fibrosis in mice.2,3 KP1 (1 mg/kg) preserves erectile function and decreases corporal apoptosis and oxidative damage in a rat model of bilateral cavernous nerve injury.4
WARNING This product is not for human or veterinary use.
1. A Klotho-
2. Klotho-
3. Klotho-
4. Klotho-